CA2383411A1 - Inhibiteurs de replication du virus de l'hepatite c - Google Patents

Inhibiteurs de replication du virus de l'hepatite c Download PDF

Info

Publication number
CA2383411A1
CA2383411A1 CA002383411A CA2383411A CA2383411A1 CA 2383411 A1 CA2383411 A1 CA 2383411A1 CA 002383411 A CA002383411 A CA 002383411A CA 2383411 A CA2383411 A CA 2383411A CA 2383411 A1 CA2383411 A1 CA 2383411A1
Authority
CA
Canada
Prior art keywords
valine
isoleucine
leucine
polypeptide
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383411A
Other languages
English (en)
Inventor
Paul L. Darke
Amanda R. Jacobs
Lawrence C. Kuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383411A1 publication Critical patent/CA2383411A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne le site de liaison de NS4A présent sur NS2/3 en tant que site cible pour inhiber l'activité protéase NS2/3. Elle concerne également des procédés permettant d'inhiber l'activité NS2/3 par ciblage du site cible identifié, ainsi que des exemples de composés utiles dans ces procédés, et une marche à suivre pour obtenir des composés utiles supplémentaires. Ces composés et procédés sont de préférence utilisés pour inhiber la réplication du virus de l'hépatite C.
CA002383411A 1999-08-30 2000-08-25 Inhibiteurs de replication du virus de l'hepatite c Abandoned CA2383411A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15139599P 1999-08-30 1999-08-30
US60/151,395 1999-08-30
PCT/US2000/023444 WO2001016379A1 (fr) 1999-08-30 2000-08-25 Inhibiteurs de replication du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
CA2383411A1 true CA2383411A1 (fr) 2001-03-08

Family

ID=22538574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383411A Abandoned CA2383411A1 (fr) 1999-08-30 2000-08-25 Inhibiteurs de replication du virus de l'hepatite c

Country Status (3)

Country Link
EP (1) EP1214454A1 (fr)
CA (1) CA2383411A1 (fr)
WO (1) WO2001016379A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0006537D0 (en) * 2000-03-17 2000-05-10 Angeletti P Ist Richerche Bio Assays and screening methods
CA2430661C (fr) 2000-12-15 2010-10-19 Boehringer Ingelheim (Canada) Ltd. Ns2/3 protease active purifiee du virus de l'hepatite (vhc)
DE10112748A1 (de) * 2001-03-14 2002-09-19 Transmit Technologietransfer Erfindung betreffend HCV-Erkrankungen
EP1551421A2 (fr) * 2002-06-21 2005-07-13 Merck & Co. Inc. Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase virale arn-dependante
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE428714T1 (de) 2004-02-24 2009-05-15 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
IT1277914B1 (it) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio Procedimento per produrre - in forma pura e in quantita' elevate - polipeptidi con l'attivita' proteolitica della proteasi ns3 di hcv, e
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease

Also Published As

Publication number Publication date
EP1214454A1 (fr) 2002-06-19
WO2001016379A1 (fr) 2001-03-08

Similar Documents

Publication Publication Date Title
Dymock Emerging therapies for hepatitis C virus infection
US20070073039A1 (en) Peptides that inhibit viral infections
Polyak et al. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon‐sensitive virus replication
CA2416603A1 (fr) Inhibition de la maturation et de la replication du virus de l'hepatite c
KR20030081297A (ko) Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
Goudreau et al. The therapeutic potential of NS3 protease inhibitors in HCV infection
Lin et al. Interferon antagonist function of Japanese encephalitis virus NS4A and its interaction with DEAD-box RNA helicase DDX42
KR20070061570A (ko) Ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제 저해
WO2002089731A9 (fr) Agents utilises dans le traitement de l'hepatite c et procedes d'utilisation
CA2383411A1 (fr) Inhibiteurs de replication du virus de l'hepatite c
AU2021360898A1 (en) Chimeric conjugates for degradation of viral and host proteins and methods of use
Liu et al. The S1′–S3′ Pocket of the SARS‐CoV‐2 Main Protease Is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors
Chen et al. The journey to the discovery of boceprevir: an NS3–NS4 HCV protease inhibitor for the treatment of chronic hepatitis C
Orrù et al. Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry
Bianchi et al. Conformational changes in human hepatitis C virus NS3 protease upon binding of product-based inhibitors
JP2000504331A (ja) システインプロテアーゼｉｃｈ―１の基質及び阻害剤
Abdullah et al. Discovery of dengue virus inhibitors
Pacheco et al. Membrane-perturbing properties of three peptides corresponding to the ectodomain of hepatitis C virus E2 envelope protein
De Francesco et al. Mechanisms of hepatitis C virus NS3 proteinase inhibitors
EP1278867B1 (fr) Fragments de ns 2/3 du vhc et leurs utilisations
WO2013178782A1 (fr) Inhibiteurs allostériques de la protéase ns3 du virus de l'hépatite c virus
Pessi A personal account of the role of peptide research in drug discovery: the case of hepatitis C 1
Kim et al. Selection and target-site mapping of peptides inhibiting HCV NS5B polymerase using phage display
US7094401B1 (en) HCV core protein binding agents for treatment of hepatitis C virus infection
EP1185663A1 (fr) Nouvelle sequence gbv

Legal Events

Date Code Title Description
FZDE Discontinued